Show simple item record

dc.contributor.authorPark, Tina
dc.contributor.authorCave, David R.
dc.contributor.authorMarshall, Christopher
dc.date2022-08-11T08:09:43.000
dc.date.accessioned2022-08-23T16:41:10Z
dc.date.available2022-08-23T16:41:10Z
dc.date.issued2015-08-07
dc.date.submitted2015-12-08
dc.identifier.citationWorld J Gastroenterol. 2015 Aug 7;21(29):8804-10. doi: 10.3748/wjg.v21.i29.8804. <a href="http://dx.doi.org/10.3748/wjg.v21.i29.8804">Link to article on publisher's site</a>
dc.identifier.issn1007-9327 (Linking)
dc.identifier.doi10.3748/wjg.v21.i29.8804
dc.identifier.pmid26269669
dc.identifier.urihttp://hdl.handle.net/20.500.14038/39827
dc.description.abstractMicroscopic colitis is a common cause of chronic, nonbloody diarrhea. Microscopic colitis is more common in women than men and usually affects patients in their sixth and seventh decade. This article reviews the etiology and medical management of microscopic colitis. The etiology of microscopic colitis is unknown, but it is associated with autoimmune disorders, such as celiac disease, polyarthritis, and thyroid disorders. Smoking has been identified as a risk factor of microscopic colitis. Exposure to medications, such as non-steroidal anti-inflammatory drugs, proton pump inhibitors, and selective serotonin reuptake inhibitors, is suspected to play a role in microscopic colitis, although their direct causal relationship has not been proven. Multiple medications, including corticosteroids, anti-diarrheals, cholestyramine, bismuth, 5-aminosalicylates, and immunomodulators, have been used to treat microscopic colitis with variable response rates. Budesonide is effective in inducing and maintaining clinical remission but relapse rate is as high as 82% when budesonide is discontinued. There is limited data on management of steroid-dependent microscopic colitis or refractory microscopic colitis. Immunomodulators seem to have low response rate 0%-56% for patients with refractory microscopic colitis. Response rate 66%-100% was observed for use of anti-tumor necrosis factor (TNF) therapy for refractory microscopic colitis. Anti-TNF and diverting ileostomy may be an option in severe or refractory microscopic colitis.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=26269669&dopt=Abstract">Link to Article in PubMed</a>
dc.rights<p>Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/</p>
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectChronic diarrhea
dc.subjectCollagenous colitis
dc.subjectEtiology of microscopic colitis
dc.subjectLymphocytic colitis
dc.subjectMicroscopic colitis
dc.subjectRefractory microscopic colitis
dc.subjectSteroid-dependent microscopic colitis
dc.subjectDigestive System Diseases
dc.subjectGastroenterology
dc.subjectImmune System Diseases
dc.titleMicroscopic colitis: A review of etiology, treatment and refractory disease
dc.typeJournal Article
dc.source.journaltitleWorld journal of gastroenterology
dc.source.volume21
dc.source.issue29
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=3628&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/2624
dc.identifier.contextkey7920043
refterms.dateFOA2022-08-23T16:41:10Z
html.description.abstract<p>Microscopic colitis is a common cause of chronic, nonbloody diarrhea. Microscopic colitis is more common in women than men and usually affects patients in their sixth and seventh decade. This article reviews the etiology and medical management of microscopic colitis. The etiology of microscopic colitis is unknown, but it is associated with autoimmune disorders, such as celiac disease, polyarthritis, and thyroid disorders. Smoking has been identified as a risk factor of microscopic colitis. Exposure to medications, such as non-steroidal anti-inflammatory drugs, proton pump inhibitors, and selective serotonin reuptake inhibitors, is suspected to play a role in microscopic colitis, although their direct causal relationship has not been proven. Multiple medications, including corticosteroids, anti-diarrheals, cholestyramine, bismuth, 5-aminosalicylates, and immunomodulators, have been used to treat microscopic colitis with variable response rates. Budesonide is effective in inducing and maintaining clinical remission but relapse rate is as high as 82% when budesonide is discontinued. There is limited data on management of steroid-dependent microscopic colitis or refractory microscopic colitis. Immunomodulators seem to have low response rate 0%-56% for patients with refractory microscopic colitis. Response rate 66%-100% was observed for use of anti-tumor necrosis factor (TNF) therapy for refractory microscopic colitis. Anti-TNF and diverting ileostomy may be an option in severe or refractory microscopic colitis.</p>
dc.identifier.submissionpathoapubs/2624
dc.contributor.departmentDepartment of Medicine, Division of Gastroenterology
dc.source.pages8804-10


Files in this item

Thumbnail
Name:
WJG_21_8804.pdf
Size:
1.190Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

<p>Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc.  This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/</p>
Except where otherwise noted, this item's license is described as <p>Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/</p>